Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Anlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer. A phase II clinical studies of small cell lung cancer (ALTER-1210) also showed that,
compared with placebo, Anlotinib could improve the patients survival and had less toxic side
effects after 2-3 line therapy. The purpose of this multicenter, randomized, prospective
study is to investigate the efficacy and safety of Anlotinib as the maintenance therapy for
Extensive-stage small cell lung cancer after combined with etoposide and cisplatin
chemotherapy.